ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
|
|
- Bernice Fowler
- 6 years ago
- Views:
Transcription
1 ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
2 HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (<1/100 AVERAGE) MULTIPLE CO-FACTORS ARE INVOLVED PLASMA VIRAL LOAD TRANSMISSION CAN WIDER HAART ACCESS THE SPREAD OF NEW INFECTIONS? SEXUALLY TRANSMITTED INFECTIONS (STI) HIV TRANSMISSION AND ACQUISITION: CAN STI CONTROL HIV SPREAD? BLOOD AND GENITAL HIV MAY CHANGE IN PARALLEL, BUT LOCAL FACTORS, E.G. STI, HAART CONCENTRATIONS MAY ALTER HIV IN DIFFERENT COMPARTMENTS BIOLOGICAL INTERVENTIONS MAY BE INFLUENCED BY BEHAVIORAL ISSUES
3 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral Therapy Maternal-child transmission partner s HIV load Rx of acute infection Blood screening Circumcision DECREASE HOST SUSCEPTIBILITY Barrier protection Treat STI PEP PREP Microbicides Vaccines Infection Control Circumcision ALTER RISK-TAKING BEHAVIOR Condom promotion Individual interventions Couples interventions Community-based interventions Structural interventions (e.g., economic)
4 Transmission rate per 100 Person-Years PLASMA HIV RNA PREDICTS LIKELIHOOD OF TRANSMISSION < > < > < > All subjects Male-to-Female Transmission Female-to-Male Transmission Source: Quinn N, et al, N Eng J Med 2000 Viral load (HIV-1 RNA copies/ml) and HIV transmission
5 HOW HIV INFECTS MUCOSA
6 Source: Wawer M et al, Lancet 1999 HSV control: Rationale for HSV-2 control to reduce HIV transmission HIV plasma RNA in the Probability of HIV infection in the HIV- partner per contacts HIV+ partner (copies/ml) HSV+ HSV- < , ,500-38, >38,
7 No. % Syphilis Among Fenway Clients: The new normal Cases Test
8 HIV RNA in Semen (Log 10 copies/ml) Acute HIV and STD episodes (Cohen and Pilcher, JID,
9 WHY ART FOR PREVENTION? HIV is spreading rapidly, more than 5 million new infections in the next year! Behavioral interventions have not resulted in long term changes in most settings Vaccines and Microbicides are years away ART is available now! HOWEVER, ART is relatively expensive, needs to be used repetitively, may result in toxicities, and can select for resistance, and may result in behavioral disinhibition.
10 HOW HAART COULD ALTER HIV TRANSMISSION: NEED TO MONITOR PARTNERS PVL SURVIVAL PLHIV GENITAL TRACT DURATION OF HIV INFECTIOUSNESS TRANSMISSION TRANSMISSION RELEVANT ISSUES: ACCESS, ADHERENCE, PREVENTION, STI RX.
11 Effects of Disease Stage and Zidovudine Therapy on the Detection of Human Immunodeficiency Virus Type 1 in Semen Deborah J. Anderson, Thomas R. O Brien, Joseph A. Politch, Adriana Martinez, George R. Seage III, Nancy Padian, Robert Horsburgh, Kenneth H. Mayer JAMA 267: , Cross-sectional (n=95) and longitudinal (n=35) studies of HIV-1 in semen from HIV+ men. Results: HIV-1 cultured from seminal plasma and semen cells Intermittent shedding HIV with leukocytospermia HIV in advanced disease stage HIV with zidovudine ART
12 T Lymphocytes and Macrophages, but not Motile Spermatozoa, are a Significant Source of HIV in Semen Alison J. Quayle, Chong Xu, Kenneth H. Mayer, Deborah J. Anderson Journal of Infectious Diseases 176: , T lymphocytes and macrophages are principal sources of HIV-1 in semen.
13 Patients (%) with detectable HIV in semen Semen HIV in patients with suppressed viral load 100 Potent ART Controls (drug naive) n=55 n=114 p< p= HIV-RNA HIV-DNA Vernazza, Cohen et al., AIDS, 2000
14 Acute Infections and HIV Prevention Rakai study: 40% of new transmissions were from acutely infected pts (Wawer, JID, 2005) Quebec study: almost ½ new infections were from recently infected pts (Brenner, JID, 2007) Using discordant HIV rapid tests results and RNA pooling, almost 2% of STD clinic pts in Malawi were identified with acute HIV infection (Pilcher, NEJM, 2005) Could the identification of hot spots of newly infected pts present opportunities for early ART and behavioral interventions to slow HIV spread?
15 Can Chronic HAART Decrease HIV Transmission? HIV INCIDENCE IN BRAZIL AND TAIWAN MULTIPLE REPORTS OF INCREASING TRANSMISSION OF RESISTANT HIV I5-30% OF NEWLY INFECTED PATIENTS HPTN 052: RCT OF HAART TO ASSESS EFFECT ON TRANSMISSION HIV discordant couples:india, Brazil, Thailand, Malawi, Zimbabwe, U.S. Early vs. later ART, CD4 >300 Monthly monitoring, couples counseling
16 Preclinical PEP/PrEP Studies NNRTI or NRTI were protective 70% to 100% Effective/exposure Emtricitabine + Tenofovir The combination was effective Even after repeated rectal exposures (14) The prophylactic activity probably reflects Long intracellular half life Activity in Macrophages High concentration in genital tissues Tsai 95; Van Rompay ; Subbarao 05; Heneine 06
17 APV (20%) LPV (5%) NFV (5%) Male Genital Tract Exposure EFV (3%) SQV (3%) RTV (3%) d4t (2%) ENF (ND) IDV (100%) NVP (70%) ABC (150%) ZDV (200%) TDF (500%) 3TC (600%) 0% 100% 200% 300% 400% 500% SQV (ND) ddi (100%) ABC (150%) IDV (200%) 3TC (400%) FTC (600%) EFV (0.6%) ZDV (200%) TDF (400%) d4t (4%) RTV (20%) DLV (20%) ATV (30%) LPV (30%) ABC (40%) APV (50%) NVP (80%) Female Genital Tract Exposure Fusion Inhibitors Nucleoside Reverse Transcriptase Inhibitors Protease Inhibitors Nonnucleoside Reverse Transcriptase Inhibitors (Kashuba et al)
18 Example: US DHHS Guidelines for Non- Occupational PEP MMWR 2005
19 NPEP IN BRAZILIAN MSM PEP (AZT/3TC) 4 day starter pack 28 day course N=200 high risk men Followed over 24.2 months 68 used PEP 109 times HIV incidence 2.9/100py 10 in those who did not use PEP (N=132) Thought partner was HIV-, Did not appreciate risk of that contact 1 in a PEP user (N=68) Risk Behavior decreased Schechter M et al (2004) JAIDS 35:
20 Patients (%) Tenofovir DF + Emtricitabine or Lamivudine for Non-Occupational PEP Treatment arms TDF/FTC (n=68) TDF/3TC (n=44) AZT/3TC (n=122) AZT/3TC+ 3 rd drug (n=119) Mainly MSM, similar between 20 NPEP arms 0 Mayer KH, et al. JAIDS Regimen Completion Rates % FTC/ TDF 87.5% TDF + 3TC 42.1%* ZDV/ 3TC *P< versus TDF-based regimens 38.8%* ZDV/ 3TC + 3 rd Drug
21 Tenofovir DF + Emtricitabine or Lamivudine for Non-Occupational PEP Tenofovir: diarrhea or abdominal discomfort Zidovudine: nausea and vomiting: AE s more serious FTC/ TDF TDF + 3TC ZDV/ 3TC ZDV/3TC + 3 rd Drug Diarrhea 47.5* Fatigue * Abdominal discomfort Nausea/ vomiting Adverse Events (%) Headache *P<0.05 and P<0.01. Mayer KH, et al. JAIDS. 2007
22 Percent Risk Behavior at Time of Incident Unprotected Anal Sex Alcohol Use Recreational Drug Use Note: TDF/3TC group reported more ua than the AZT/3TC group (30%), and about the same as the AZT/3TC+1 group (52%).
23 RISK BEHAVIOR IS NOT UNIFORM Calendar-based retrospective history on newly infected MSM Susceptible period from 3 months before last negative to first HIV positive test Each row represents a newly infected MSM Each dot represents a report of at least one unprotected anal or oral sex contact with HIV positive or unknown partner S Buchbinder 2005
24 Phase 2, Randomized, Double Blinded, Placebo Controlled Trial Conducted between June 2004 and March 2006 Cameroon; Nigeria; Ghana Objective: Determine the safety and preliminary effectiveness of a daily dose of 300 mg oral TDF vs Placebo for HIV prevention among high risk women also receiving HIV testing, counseling, and condoms Safety Evaluated in N=936 including 428 Person Years
25 HIV Seroconversions 8 on-product seroconversions 2 TDF : 6 placebo Difference is not statistically significant 95% confidence interval = p = 0.24 On TDF seroconversions occurred after 1 and 2 months on product, neither TDF-R Baseline Specimens were not available Peterson, Plos Clinical Trials, 2007
26 Sexual Behavior During PREP Trial in West Africa Screening Follow-up Number of partners (30 days) Number of new partners (30 days) Number of sex acts (7 days) Condom use (last act) % 94% Peterson, XVI AIDS Conference, Toronto, 2006
27 PREP and Drug Resistance? TDF/FTC resistance comes with a high fitness cost Monotherapy with TDF No resistance detected after 28d in people (Barditch-Crovo 2001) Resistant minor variants enriched in monkeys (Van Rampay 2007) Non-human primate studies TDF PEP partially effective vs drug resistant SIV (Van Rompay 2000) No TDF resistance after TDF or FTC/TDF failure (Subbarao 2006) FTC resistance intermittently detected (Garcia Lerma 2007) TDF and FTC resistance Makes AZT more active, but diminishes activity of other nrtis Has no effect on other classes of drugs
28
29 CDC U.S. MSM PrEP Study (Project T; Project PrEPare) 100 TDF 100 Placebo 100 No Pills TDF 100 No Pills Placebo Enrollment 9 months 24 months
30 PrEP is not already in wide use Outcome Overall (n=851) SF Bay Area (n=403) Circuit Party (n=176) STD Clinic (n=272) Heard of PrEP 18% 20% 19% 15% Knew PrEP user 2% 2% 4% 2% Used PrEP 0.12% 0% 0% 0.39% 1 Would use PrEP if safe/effective 68% (n=563) 69% 66% n/a 1 Had not heard of PrEP and received 30 days of medication from clinician may have been post-exposure prophylaxis (1 month of antiretroviral therapy started shortly after high-risk exposure) Liu, IAS, 2006
31 An orally delivered CCR5 inhibitor Provided partial protection of macaques from SHIV-162P3 vaginal transmission Condition Infected p-value Controls (no inhibitor, including historic controls) 16/18 CMPD 167 for 4 days prior to challenge 3/ CMPD 167 for 10 days post challenge (inc. day 0) 4/ CMPD 167 for 4 days prior + 10 days post challenge 6/ (CMPD 167 +/- 4 days prior + 10 days post challenge 10/ ) Courtesy of John Moore
32 WHERE MICROBICIDES MAY WORK
33 Oral vs. Topical PrEP? (HPTN 050) 1000 PMPA ng/ml LLOQ Hours
34 NEW ART FOR PREVENTION STUDIES: DRUGS, FREQUENCY, & ROUTE Karim: TDF Vaginal Gel dose just before and just after intercourse MTN: Oral vs. topical chemoprophylaxis; design challenges, double randomization New agents, combinations? Important to have sufficient studies to understand dosing regimens/trade offs using combinations (e.g. cost, AEs, efficacy, adherence)
35 HIV incidence among IDUs has been declining in the U.S.
36 Multivariable analysis of seroconversion risk: Drug use in Explore Drug N at baseline No. of infections Hazard ratio* (95% CI) Heavy alcohol** (1.2, 2.8) Amphetamines (1.4, 2.6) Alcohol/drugs before sex (1.1, 2.3) *REF = no/light/moderate use of alcohol; no speed use; no use before sex ** 4+ drinks every day or 6+ drinks on a typical day
37 CONCLUSIONS Vaccines are years away, antiretrovirals are available now However, because they will need to be used recurrently and are not expected to be 100% protective, further studies of pharmacology, virology and behavioral sciences will be needed to best understand their intended and unintended consequences. They may become part of HAARP: highly active antiretroviral prevention
ART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationHIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07
HIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07 Estimates of Per-Contact Risk of HIV Infection HIV TRANSMISSION SIGNIFICANT, LOW
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationHIV Prevention: 2010
Antiretrovirals for Prevention: Opportunities and Challenges for TREAT Asia KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY HEALTH HIV Prevention: 2010 DECREASE SOURCE OF INFECTION Barrier
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationPost exposure prophylaxis following exposure to HIV. Paul Benn Mortimer Market Centre, Camden PCT HIVPA study day Tuesday 18 th November 2008 SOAS
Post exposure prophylaxis following exposure to HIV Paul Benn Mortimer Market Centre, Camden PCT HIVPA study day Tuesday 18 th November 2008 SOAS Overview Hypothesis PEP? Awareness & uptake PEP/PEPSE Ensuring
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationSEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations
SEXUAL TRANSMISSION under ART: Biological Considerations Dr Steve Taylor, MB ChB, FRCP, PhD Consultant Physician, HIV/GU Medicine, Lead Consultant HIV Services, Directorate of Sexual Medicine and HIV Birmingham
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationWorking to End the HIV Pandemic: Glimmers of Hope. Transmission of HIV-1 Biological Requirements
Working to End the HIV Pandemic: Glimmers of Hope Myron S. Cohen, MD Director, Institute for Global Health The University of North Carolina Transmission of HIV-1 Biological Requirements Infectious Inoculum
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationPharmacology Considerations for HIV Prevention
Pharmacology Considerations for HIV Prevention Peter L. Anderson University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Perspectives for next generation studies
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationThe Synergy between HIV and other STIs
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationPre-exposure Prophylaxis (PrEP)
Pre-exposure Prophylaxis (PrEP) Kenneth Mayer, MD Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School and School of Public Health Treatment As Prevention in Africa Workshop May 2
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationHIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic
HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic Yes No What s Going on Out There? Condomless Sex among
More informationMaraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers
Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers Julie B. Dumond, Kristine B. Patterson, Allison Pecha, Rebecca E. Werner, Emma Andrews,* Bharat Damle,*
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationADM Kashuba, PharmD, Eshelman School of Pharmacy, UNC Chapel Hill
ADM Kashuba, PharmD, Eshelman School of Pharmacy, UNC Chapel Hill Stroma Is there an ARV target conc n to abort HIV infection in the stroma? Fauci A. WAC 2010 Monkey Plasma Concentration Relative to Human
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationTreatment as Prevention in India: What will it take?
Treatment as Prevention in India: What will it take? Suniti Solomon, MD FAMS Director, YRGCARE August 26, 2011 ICAAP 10, Busan, South Korea HIV IN INDIA The First Evidence The Numbers.. Source: NACO Prevalence
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationOverview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationHIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR)
HIV/AIDS: Outline HIV/AIDS 2013 Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City January 31, 2013 Epidemiology
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationFAMILY HIV CENTER NJ CARES SANE
HIV, Hepatitis B & C Postexposure Prophylaxis for Sexual Assault Victims Update for Case Managers Susan Burrows-Clark, RN, MSN, CNS, C. 10/17/11 Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationPsychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD
Psychosocial Issues in ART and HIV Prevention Steven A. Safren, PhD MSM, Mental Health, and Sexual Health 1. Why is behavioral science important when using ART as prevention? 2. How can we address the
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationContraceptive Research and Development Organization
COMMONLY USED ABBREVIATIONS AND ACRONYMS IN MTN PROTOCOLS 3TC ACASI AE AIDS ALT ART ARV AST AUC BMD BV CDC cgmp CFR CI CONRAD Cmax Cmin CORE C-PMPA lamivudine audio computer-assisted self interview adverse
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationNon-occupational HIV Post Exposure Prophylaxis (npep)
Mountain West AIDS Education and Training Center Non-occupational HIV Post Exposure Prophylaxis (npep) Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPEP and PrEP. Yvonne Gilleece Consultant in HIV Brighton & Sussex University Hospitals NHS Trust
PEP and PrEP Yvonne Gilleece Consultant in HIV Brighton & Sussex University Hospitals NHS Trust UNAIDS 90-90-90: HIV Treatment Targets for 2020 with Global Estimates (2014) 100% 80% 60% Target 1: 90% of
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationPre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
More informationSexual transmission of HIV: a heterogeneous event
Sexual transmission of HIV: a heterogeneous event Deutsch-Österreichischer AIDS Kongress Wien 1.-4. June 2005 Pietro L. Vernazza, Infectious Diseases, KSSG St. Gallen, Switzerland Heterosexual Transmission
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationPEP, PREP, HPTN052 and MLN2238
PEP, PREP, HPTN052 and MLN2238 Understanding the alphabet soup of HIV prevention and cure strategies Christina G Rivera, PharmD, BCPS Pharmacy Grand Rounds August 15, 2017 2017 MFMER slide-1 Presentation
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
More information